This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
8h
Zacks.com on MSNWhy the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained TodayVertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close.
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...
6d
MoneyWeek on MSNVertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
The stock's fall snapped a four-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results